ArticleACS sensors2021
Microfluidic Magneto Immunosensor for Rapid, High Sensitivity Measurements of SARS-CoV-2 Nucleocapsid Protein in Serum.
Article in ACS sensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2022Pooled it
- Electronic and electrochemical viral detection for point-of-care use: A systematic review.PloS one · 2021Pooled it
- Efficient fabrication of paper-based microfluidic biosensors incorporating laser-induced graphene for label-free electrochemical immunoassays.Mikrochimica acta · 2026Article
- Advances on Sensors and Diagnostics of SARS-CoV-2 Biomarkers.Analytical chemistry · 2026Article
- Innovation landscape in nanobiosensors for COVID-19 detection and future implications for a resilient Global Health Security.3 Biotech · 2025Review
- Unleashing Monoclonal Antibodies: Targeting Covid-19's Nucleocapsid Protein and Spike Antigens.Archives of Razi Institute · 2025Article
- Ultrasensitive detection of intact SARS-CoV-2 particles in complex biofluids using microfluidic affinity capture.Science advances · 2025Article
- Artificial intelligence-powered electrochemical sensor: Recent advances, challenges, and prospects.Heliyon · 2024Review
- Highly Reusable Electrochemical Immunosensor for Ultrasensitive Protein Detection.Advanced sensor research · 2024Article
- Advancing Microfluidic Immunity Testing Systems: New Trends for Microbial Pathogen Detection.Molecules (Basel, Switzerland) · 2024Review
- Utilizing COVID-19 as a Model for Diagnostics Using an Electrochemical Sensor.Sensors (Basel, Switzerland) · 2024Article
- Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era.Nano convergence · 2024Review
- Smartphone-based point-of-care testing of the SARS-CoV-2: A systematic review.Scientific African · 2023Article
- Metallic nanoplatforms for COVID-19 diagnostics: versatile applications in the pandemic and post-pandemic era.Journal of nanobiotechnology · 2023Review
- Biopanning of specific peptide for SARS-CoV-2 nucleocapsid protein and enzyme-linked immunosorbent assay-based antigen assay.Analytica chimica acta · 2023Article
- Internet-of-medical-things integrated point-of-care biosensing devices for infectious diseases: Toward better preparedness for futuristic pandemics.Bioengineering & translational medicine · 2023Review
- Using Nanomaterials for SARS-CoV-2 Sensing via Electrochemical Techniques.Micromachines · 2023Review
- β-Cyclodextrin Polymer-Based Fluorescence Enhancement Strategy via Host-Guest Interaction for Sensitive Assay of SARS-CoV-2.International journal of molecular sciences · 2023Article
- Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions.Biomedical microdevices · 2023Review
- Recent development of microfluidics-based platforms for respiratory virus detection.Biomicrofluidics · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The COVID-19 pandemic has highlighted the importance and urgent need for rapid and accurate diagnostic tests for COVID-19 detection and screening. The objective of this work was to develop a simple immunosensor for rapid and high sensitivity measurements of SARS-CoV-2 nucleocapsid protein in serum. This assay is based on a unique sensing scheme utilizing dually-labeled magnetic nanobeads for immunomagnetic enrichment and signal amplification. This immunosensor is integrated onto a microfluidic chip, which offers the advantages of minimal sample and reagent consumption, simplified sample handling, and enhanced detection sensitivity. The functionality of this immunosensor was validated by using it to detect SARS-CoV-2 nucleocapsid protein, which could be detected at concentrations as low as 50 pg/mL in whole serum and 10 pg/mL in 5× diluted serum. We also adapted this assay onto a handheld smartphone-based diagnostic device that could detect SARS-CoV-2 nucleocapsid protein at concentrations as low as 230 pg/mL in whole serum and 100 pg/mL in 5× diluted serum. Lastly, we assessed the capability of this immunosensor to diagnose COVID-19 infection by testing clinical serum specimens, which revealed its ability to accurately distinguish PCR-positive COVID-19 patients from healthy, uninfected individuals based on SARS-CoV-2 nucleocapsid protein serum levels. To the best of our knowledge, this work is the first demonstration of rapid (<1 h) SARS-CoV-2 antigen quantification in whole serum samples. The ability to rapidly detect SARS-CoV-2 protein biomarkers with high sensitivity in very small (<50 μL) serum samples makes this platform a promising tool for point-of-care COVID-19 testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.